Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
3.650
+0.040 (1.11%)
At close: Mar 9, 2026, 4:00 PM EDT
3.690
+0.040 (1.10%)
After-hours: Mar 9, 2026, 7:56 PM EDT
Company Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders.
The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass.
It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations.
Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Alaunos Therapeutics, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Holger Weis |
Contact Details
Address: 2617 Bissonnet Street, Suite 233 Houston, Texas 77005 United States | |
| Phone | 346 355 4099 |
| Website | alaunos.com |
Stock Details
| Ticker Symbol | TCRT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001107421 |
| CUSIP Number | 98973P101 |
| ISIN Number | US98973P3091 |
| Employer ID | 84-1475642 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ferdinand Groenewald | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | SCHEDULE 13D/A | Filing |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 24, 2026 | SCHEDULE 13D/A | Filing |
| Jan 8, 2026 | 8-K | Current Report |
| Dec 23, 2025 | 8-K | Current Report |
| Dec 11, 2025 | 424B8 | Filing |
| Dec 5, 2025 | SCHEDULE 13D/A | Filing |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 7, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Oct 31, 2025 | SCHEDULE 13D/A | Filing |